What AEZS Bashers Do NOT want to Discuss
1. Net 16 million share bank accumulation in Q1 2015 (see morningstar or nasdaq.com)
2. 37 million dollars cash paid by 3 banks for Warrants convertible to common shares at .62 and .81 cents.
3. The Class C Warrants were prepaid by those 3 banks with an exercise price of 81 cents (very telling) convert to common shares.
4. The Class A and B Warrants have 62 cent exercise price, were not prepaid, and the cash fronted for those came with a cashlesss exercise provision, where they could sell a % of those warrant shares into market to pay for remaining warrant shares to be exercised. Formula provided via 6k in sec.gov specifies formula to determine how many shares they can convert and how many they have to sell to exercise.
5. Company 6k in sec.gov specifies 79 million shares to be the dilution once warrants are fully executed.
6. Company has a rich Suite of Patents consisting of over 80 families of patents (each family containing one or more patents)
7. Company announced on 7/28, a licencing of one of their patented products with another company (new revenue stream)
8. Company announced on 7/29, another licensing of another product with another company (another new revenus stream)
9. Company has indicated to expect the partnership for their Estrogen product to generate much higher revenues on next Q numbers.
10. Company has indicated they intend to leverate their patented product suites to raise profits and pay for further product pipeline testing.
11. Bonus! They have two phase 3 products (final state of FDA testing) that the 3 banks offering the 37 million cash in exchange for common shares of AEZS at .62 and .81 is the REASON they are VERY interested in AEZS.
